In Bolivia desperate family leaves coffin in the street

Funeral workers carry the coffin with the remains of a victim of COVID-19 who died a week ago and had been left on the street by their relatives in Cochabamba, Bolivia on July 4, 2020. (AFP / DIEGO CARTAGENA)
Short Url
Updated 04 July 2020

In Bolivia desperate family leaves coffin in the street

  • The Andean nation has reported 36,818 confirmed cases of COVID-19 and 1,320 deaths

LA PAZ, Bolivia: The rising toll of COVID-19 deaths is overwhelming the Bolivian city of Cochabamba, where desperate relatives of one apparent victim of the new coronavirus left his coffin in the street for several hours on Saturday to protest difficulties in getting him buried.
Neighbor Remberto Arnez said the 62-year-old man had died on Sunday and his body had been in his home ever since, “but that’s risky because of the possible contagion.”
After a few hours, funeral workers showed up and took the coffin to a cemetery.
Police Col. Iván Rojas told a news conference that the city is collecting “about 17 bodies a day. This is collapsing the police personnel and funeral workers” in the city of some 630,000 people.
“The crematorium oven is small, that that is where the bodies are collecting,” said national Labor Minister Óscar Mercado, who told reporters that officials were preparing 250 new burial plots in the city’s main cemetery.
The Andean nation has reported 36,818 confirmed cases of COVID-19 and 1,320 deaths.


US to pay over $1 bn for 100 mln doses of J&J’s potential COVID-19 vaccine

Updated 05 August 2020

US to pay over $1 bn for 100 mln doses of J&J’s potential COVID-19 vaccine

  • The latest contract equates to roughly $10 per vaccine dose produced by J&J
  • This is J&J’s first deal to supply its investigational vaccine to a country

WASHINGTON: The United States government will pay Johnson & Johnson over $1 billion for 100 million doses of its potential coronavirus vaccine, its latest such arrangement as the race to tame the pandemic intensifies, the drugmaker said on Wednesday.
It said it would deliver the vaccine to the Biomedical Advanced Research and Development Authority (BARDA) on a not-for-profit basis to be used after approval or emergency use authorization by the US Food and Drug Administration (FDA).
J&J has already received $1 billion in funding from the US government — BARDA agreed in March to provide that money for the company to build manufacturing capacity for more than 1 billion doses of the experimental vaccine.
The latest contract equates to roughly $10 per vaccine dose produced by J&J. Including the first $1 billion deal with the USgovernment, the price would be slightly higher than the $19.50 per dose that the United States is paying for the vaccine being developed by Pfizer Inc. and German biotech BioNTech SE.
The US government may also purchase an additional 200 million doses under a subsequent agreement. J&J did not disclose that deal’s value.
J&J plans to study a one- or two-dose regimen of the vaccine in parallel later this year. A single-shot regimen could allow more people to be vaccinated with the same number of doses and would sidestep issues around getting people to come back for their second dose.
This is J&J’s first deal to supply its investigational vaccine to a country. Talks are underway with the European Union, but no deal has yet been reached.
J&J’s investigational vaccine is currently being tested on healthy volunteers in the United States and Belgium in an early-stage study.
There are currently no approved vaccines for COVID-19. More than 20 are in clinical trials.